24O Stock Overview
Provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
ReShape Lifesciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.11 |
| 52 Week High | US$63.25 |
| 52 Week Low | US$4.77 |
| Beta | 1.33 |
| 11 Month Change | 0% |
| 3 Month Change | -99.28% |
| 1 Year Change | -99.79% |
| 33 Year Change | n/a |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 24O | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | -0.1% |
| 1Y | -99.8% | 0.7% | 2.3% |
Return vs Industry: 24O underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: 24O underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 24O volatility | |
|---|---|
| 24O Average Weekly Movement | 38.0% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 24O's share price has been volatile over the past 3 months.
Volatility Over Time: 24O's weekly volatility has increased from 19% to 38% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 47 | Paul Hickey | www.reshapelifesciences.com |
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus.
ReShape Lifesciences Inc. Fundamentals Summary
| 24O fundamental statistics | |
|---|---|
| Market cap | €3.50m |
| Earnings (TTM) | -€59.87m |
| Revenue (TTM) | €10.37m |
0.3x
P/S Ratio-0.1x
P/E RatioIs 24O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 24O income statement (TTM) | |
|---|---|
| Revenue | US$11.27m |
| Cost of Revenue | US$4.29m |
| Gross Profit | US$6.98m |
| Other Expenses | US$72.04m |
| Earnings | -US$65.06m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -134.55 |
| Gross Margin | 61.91% |
| Net Profit Margin | -577.18% |
| Debt/Equity Ratio | 0% |
How did 24O perform over the long term?
See historical performance and comparison